Norepinephrine involvement in antidepressant action.
Norepinephrine involvement in antidepressant action.
复制标题
DOI：
--
复制
发表时间：
2000-08
期刊：
影响因子：
--
通讯作者：
A. Frazer
中科院分区：
文献类型：
--
作者：
A. Frazer
由于选择性5-羟色胺再摄取抑制剂（SSRI）抗抑郁药的引入和普及，很多注意力都集中在吲哚烷基胺5-羟色胺或5-羟色胺上。在某种程度上，这种对血清素的关注是以牺牲儿茶酚胺神经递质去甲肾上腺素为代价的。然而，近40年来，去甲肾上腺素再摄取的选择性阻断剂可能是抗抑郁药（例如，地昔帕明）。这篇简短的评论涵盖了急性药理学作用，可能是负责目前上市的抗抑郁药的疗效，以及reboxeratin，一种新开发的选择性去甲肾上腺素再摄取抑制剂。还讨论了这样一个事实，即选择性再摄取抑制剂的急性药理学特征往往预测长期给药时产生的影响。例如，长期服用SSRIs会对肾上腺素能系统产生一定的影响，但对去甲肾上腺素能系统没有影响。相比之下，选择性去甲肾上腺素再摄取抑制剂，当给予长期，修改某些去甲肾上腺素能参数，但不是肾上腺素能指数。最后，它是推测如何增强中枢去甲肾上腺素传递的药物可能会改善抑郁症的症状。
Because of the introduction and popularity of the selective serotonin reuptake inhibitor (SSRI) antidepressants, much attention was centered on the indolealkylamine 5-hydroxytryptamine, or serotonin. To some extent, this focus on serotonin occurred at the expense of the catecholamine neurotransmitter norepinephrine. Nevertheless, it has been apparent for almost 40 years that selective blockers of norepinephrine reuptake may be antidepressants (e.g., desipramine). This brief review covers the acute pharmacologic effects that may be responsible for the efficacy of currently marketed antidepressants as well as that of reboxetine, a newly developed selective norepinephrine reuptake inhibitor. Also discussed is the fact that the acute pharmacologic profile of selective reuptake inhibitors often predicts effects they produce when given long term. For example, the long-term administration of SSRIs produces certain effects on serotonergic systems, but not noradrenergic ones. By contrast, selective norepinephrine reuptake inhibitors, when given long term, modify certain noradrenergic parameters, but not serotonergic indices. Finally, it is speculated how drugs that enhance central noradrenergic transmission might ameliorate the symptoms of depression.